Literature DB >> 27420737

Design and Characterization of Superpotent Bivalent Ligands Targeting Oxytocin Receptor Dimers via a Channel-Like Structure.

Marta Busnelli1,2, Gunnar Kleinau3, Markus Muttenthaler4, Stoytcho Stoev5, Maurice Manning5, Lucka Bibic6, Lesley A Howell6, Peter J McCormick6, Simona Di Lascio2, Daniela Braida2, Mariaelvina Sala1,2, G Enrico Rovati7, Tommaso Bellini2, Bice Chini1.   

Abstract

Dimeric/oligomeric states of G-protein coupled receptors have been difficult to target. We report here bivalent ligands consisting of two identical oxytocin-mimetics that induce a three order magnitude boost in G-protein signaling of oxytocin receptors (OTRs) in vitro and a 100- and 40-fold gain in potency in vivo in the social behavior of mice and zebrafish. Through receptor mutagenesis and interference experiments with synthetic peptides mimicking transmembrane helices (TMH), we show that such superpotent behavior follows from the binding of the bivalent ligands to dimeric receptors based on a TMH1-TMH2 interface. Moreover, in this arrangement, only the analogues with a well-defined spacer length (∼25 Å) precisely fit inside a channel-like passage between the two protomers of the dimer. The newly discovered oxytocin bivalent ligands represent a powerful tool for targeting dimeric OTR in neurodevelopmental and psychiatric disorders and, in general, provide a framework to untangle specific arrangements of G-protein coupled receptor dimers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27420737     DOI: 10.1021/acs.jmedchem.6b00564

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  23 in total

1.  A Comparison of the Ability of Leu8- and Pro8-Oxytocin to Regulate Intracellular Ca2+ and Ca2+-Activated K+ Channels at Human and Marmoset Oxytocin Receptors.

Authors:  Marsha L Pierce; Suneet Mehrotra; Aaryn C Mustoe; Jeffrey A French; Thomas F Murray
Journal:  Mol Pharmacol       Date:  2019-02-09       Impact factor: 4.436

2.  Delineation of molecular determinants for FR900359 inhibition of Gq/11 unlocks inhibition of Gαs.

Authors:  Michael W Boesgaard; Kasper Harpsøe; Michelle Malmberg; Christina R Underwood; Asuka Inoue; Jesper M Mathiesen; Gabriele M König; Evi Kostenis; David E Gloriam; Hans Bräuner-Osborne
Journal:  J Biol Chem       Date:  2020-08-04       Impact factor: 5.157

Review 3.  Oxytocin structure and function in New World monkeys: from pharmacology to behavior.

Authors:  Aaryn Mustoe; Jack H Taylor; Jeffrey A French
Journal:  Integr Zool       Date:  2018-11       Impact factor: 2.654

Review 4.  Bench-top to clinical therapies: A review of melanocortin ligands from 1954 to 2016.

Authors:  Mark D Ericson; Cody J Lensing; Katlyn A Fleming; Katherine N Schlasner; Skye R Doering; Carrie Haskell-Luevano
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-03-29       Impact factor: 5.187

5.  A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

Authors:  Cody J Lensing; Danielle N Adank; Stacey L Wilber; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-02-16       Impact factor: 4.418

6.  The Current Status of Drug Discovery for the Oxytocin Receptor.

Authors:  Philippe E Nashar; Aidan A Whitfield; Jiri Mikusek; Tristan A Reekie
Journal:  Methods Mol Biol       Date:  2022

Review 7.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

Review 8.  Cross-talk among oxytocin and arginine-vasopressin receptors: Relevance for basic and clinical studies of the brain and periphery.

Authors:  Zhimin Song; H Elliott Albers
Journal:  Front Neuroendocrinol       Date:  2017-10-18       Impact factor: 8.606

9.  Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor.

Authors:  Marsha L Pierce; Jeffrey A French; Thomas F Murray
Journal:  Biomed Pharmacother       Date:  2020-03-04       Impact factor: 6.529

10.  Subtle modifications to oxytocin produce ligands that retain potency and improved selectivity across species.

Authors:  Markus Muttenthaler; Åsa Andersson; Irina Vetter; Rohit Menon; Marta Busnelli; Lotten Ragnarsson; Christian Bergmayr; Sarah Arrowsmith; Jennifer R Deuis; Han Sheng Chiu; Nathan J Palpant; Margaret O'Brien; Terry J Smith; Susan Wray; Inga D Neumann; Christian W Gruber; Richard J Lewis; Paul F Alewood
Journal:  Sci Signal       Date:  2017-12-05       Impact factor: 8.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.